查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587399

生物製药契约製造市场规模、份额和趋势分析报告：按供应商、按服务、按药物类型、按类型、按业务规模、按治疗领域、按地区和细分市场预测，2025-2030年

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report By Source, By Service, By Drug Type, By Type, By Scale of Operation, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

生物製药契约製造市场的成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球生物製药契约製造市场规模预计将达到758亿美元，2025年至2030年复合年增长率为11.1%。

生物製药管道的成长和缺乏足够的製造能力是推动聚合物製造商和契约製造组织 (CMO) 之间合作的两个关键因素。契约製造正在扩大其服务组合，以满足企业对监管标准和新服务的需求。然而，大流行也产生了负面影响，预算和资源被转移到「新冠产品」上，而牺牲了其他治疗领域正在开发的其​​他生技药品计划。

由于 CMO 采取的变革，预计在预测期内，公司对 CMO 生产生技药品和生物相似药的依赖将会增加。公司与 CMO 之间合作投资的增加以及不断努力扩大其服务组合证明了这一点。生物製药供应链强大，在冠状病毒大流行期间，全球基本上未受到影响。生物製药契约製造也看到了对 COVID-19 疫苗和治疗药物的需求增加。因此，未来市场蕴藏着许多机会。例如，2020年，Astra Zeneca和牛津生物医学公司签订了为期一年的临床和商业供应协议，用于生产Astra Zeneca的COVID-19候选疫苗AZD1222。

市场的未来成长高度依赖生物製药、生物加工和合约服务产业提供的有前景的机会。生命科学领域灌装和加工服务的扩展以及强劲的创业投资投资是预计推动市场发展的两个关键机会。例如，2019年，上海海和生物製药有限公司为大型抗癌药物组合筹集了1.466亿美元的创业投资，并与外包合作伙伴浙江九洲药业有限公司进行了槓桿收购。

生物製药契约製造市场报告亮点

  • 由于哺乳动物表现系统在生技药品开发中的高度普及，到 2024 年，基于哺乳动物的生物製药契约製造将占据最大市场占有率，约为 57.1%。
  • 由于高资本投资，特别是下游工艺，工艺开拓服务在 2024 年将占据全球市场最大的收入份额。
  • 由于对生技药品製造的高需求，生物製药契约製造在该领域占据主导地位。然而，由于生物相似药的发展具有降低成本的好处，预计生物相似药产业在预测期内将实现最快的复合年增长率。
  • 由于有有效的生技药品开发法规结构，美国在 2024 年将占据北美市场 34.3% 的巨大份额。
  • 亚太地区生物製药契约製造市场正在以良好的速度成长，印度和中国等新兴经济体正在采取措施保持竞争力，预计将成为一个快速成长的地区。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章生物製药契约製造市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产品平臺分析
  • 定价模式分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析

第四章生物製药契约製造市场：供应商估算及趋势分析

  • 细分仪表板
  • 供应商波动分析
  • 供应商，2018-2030
  • 哺乳动物的
  • 非哺乳动物

第五章生物製药契约製造市场：服务评估与趋势分析

  • 细分仪表板
  • 服务波动分析
  • 按服务划分，2018-2030
  • 製程开发
    • 下游加工
    • 上游加工
  • 填充和整理操作
  • 分析和品管研究
  • 包装和标籤

第六章 生物製药契约製造市场：药品种类预估及趋势分析

  • 细分仪表板
  • 药物类型变异分析
  • 依药物类型，2018-2030
  • 生物製药
    • 单株抗体
    • 重组蛋白
    • 疫苗
    • 反义、RNAi、分子治疗
    • 其他的
  • 生物相似药

第七章 生物製药契约製造市场：类型估计和趋势分析

  • 细分仪表板
  • 类型变异分析
  • 按类型，2018-2030
  • 药物成分
  • 成品药

第八章生物製药契约製造市场：业务规模估算及趋势分析

  • 细分仪表板
  • 业务规模变化分析
  • 2018-2030年按业务规模划分
  • 临床
  • 商业的

第九章生物製药契约製造市场：治疗领域的估算与趋势分析

  • 细分仪表板
  • 治疗区域变化分析
  • 依治疗领域，2018-2030
  • 瘤
  • 自体免疫疾病
  • 感染疾病
  • 心血管疾病
  • 代谢性疾病
  • 神经病学
  • 其他的

第10章生物製药契约製造市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第十一章竞争格局

  • 公司分类
    • 市场领导者
    • 新兴企业
  • 2024 年企业市场分析（企业热图分析）
  • 公司简介
    • Boehringer Ingelheim GmbH
    • Lonza
    • Inno Biologics Sdn Bhd
    • Rentschler Biotechnologies GmbH
    • JRS PHARMA
    • AGC Biologics
    • ProBioGen
    • FUJIFILM Diosynth Biotechnologies USA, Inc.
    • Toyobo Co. Ltd.
    • Samsung Biologics
    • Thermo Fisher Scientific, Inc.
    • Binex Co., Ltd.
    • WuXi Biologics
    • AbbVie, Inc.
    • ADMA Biologics, Inc.
    • Catalent, Inc
    • Cambrex Corporation
    • Pfizer Inc.
    • Siegfried Holding AG
Product Code: GVR-2-68038-698-1

Biopharmaceuticals Contract Manufacturing Market Growth & Trends:

The global biopharmaceuticals contract manufacturing market size is estimated to reach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to "COVID products" at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Biopharmaceuticals Contract Manufacturing Market Report Highlights:

  • Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing to the high penetration of mammalian expression systems for biologics development
  • Process development services held the largest revenue share in the global market in 2024., owing to high capital investment, especially in downstream process
  • Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, The biosimilar segment is anticipated to register the fastest CAGR over the forecast period due to cost-saving advantages associated with biosimilars development
  • The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024
  • Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected to emerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing to developing economies such as India and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rise in investment by CMOs for capacity expansion
      • 3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
      • 3.2.1.3. Notable growth of biologics approvals
      • 3.2.1.4. Robust biopharmaceuticals pipeline
      • 3.2.1.5. Cost and time-saving benefits offered by contract services
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
      • 3.2.2.2. Managing Relationships
  • 3.3. Product Pipeline Analysis
  • 3.4. Pricing Model Analysis
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Source Movement Analysis
  • 4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
  • 4.4. Mammalian
    • 4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Non-mammalian
    • 4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Service Movement Analysis
  • 5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Downstream Processing
      • 5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Upstream Processing
      • 5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Fill & Finish Operations
    • 5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Analytical & QC Studies
    • 5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Packaging & Labelling
    • 5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Drug Type Movement Analysis
  • 6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
  • 6.4. Biologics
    • 6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Monoclonal Antibodies
      • 6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Recombinant proteins
      • 6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Vaccines
      • 6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Antisense, RNAi, & Molecular Therapy
      • 6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Biosimilar
    • 6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceuticals Contract Manufacturing Market: Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Type Movement Analysis
  • 7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
  • 7.4. Drug Substance
    • 7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Finished Drug Product
    • 7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Scale of Operation Movement Analysis
  • 8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
  • 8.4. Clinical
    • 8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Commercial
    • 8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Therapeutic Area Movement Analysis
  • 9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
  • 9.4. Oncology
    • 9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Autoimmune Diseases
    • 9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Infectious Diseases
    • 9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7. Cardiovascular Diseases
    • 9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8. Metabolic Diseases
    • 9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.9. Neurology
    • 9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.10. Others
    • 9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional market share analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. North America
    • 10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2. U.S.
      • 10.3.2.1. Key Country Dynamics
      • 10.3.2.2. Competitive Scenario
      • 10.3.2.3. Regulatory Landscape
      • 10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.3. Canada
      • 10.3.3.1. Key Country Dynamics
      • 10.3.3.2. Competitive Scenario
      • 10.3.3.3. Regulatory Landscape
      • 10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.4. Mexico
      • 10.3.4.1. Key Country Dynamics
      • 10.3.4.2. Competitive Scenario
      • 10.3.4.3. Regulatory Landscape
      • 10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4. Europe
    • 10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2. U.K.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Landscape
      • 10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.3. Germany
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Landscape
      • 10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.4. France
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Landscape
      • 10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.5. Italy
      • 10.4.5.1. Key Country Dynamics
      • 10.4.5.2. Competitive Scenario
      • 10.4.5.3. Regulatory Landscape
      • 10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.6. Spain
      • 10.4.6.1. Key Country Dynamics
      • 10.4.6.2. Competitive Scenario
      • 10.4.6.3. Regulatory Landscape
      • 10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.7. Denmark
      • 10.4.7.1. Key Country Dynamics
      • 10.4.7.2. Competitive Scenario
      • 10.4.7.3. Regulatory Landscape
      • 10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.8. Sweden
      • 10.4.8.1. Key Country Dynamics
      • 10.4.8.2. Competitive Scenario
      • 10.4.8.3. Regulatory Landscape
      • 10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.9. Norway
      • 10.4.9.1. Key Country Dynamics
      • 10.4.9.2. Competitive Scenario
      • 10.4.9.3. Regulatory Landscape
      • 10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5. Asia Pacific
    • 10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2. China
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Landscape
      • 10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.3. Japan
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Landscape
      • 10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.4. India
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Landscape
      • 10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.5. South Korea
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Landscape
      • 10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.6. Australia
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Landscape
      • 10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.7. Thailand
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Landscape
      • 10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6. Latin America
    • 10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2. Brazil
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Landscape
      • 10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.3. Argentina
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Landscape
      • 10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7. Middle East and Africa
    • 10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.2. Saudi Arabia
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Landscape
      • 10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.3. UAE
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Landscape
      • 10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.4. South Africa
      • 10.7.4.1. Key Country Dynamics
      • 10.7.4.2. Competitive Scenario
      • 10.7.4.3. Regulatory Landscape
      • 10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.5. Kuwait
      • 10.7.5.1. Key Country Dynamics
      • 10.7.5.2. Competitive Scenario
      • 10.7.5.3. Regulatory Landscape
      • 10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
  • 11.3. Company Profiles
    • 11.3.1. Boehringer Ingelheim GmbH
      • 11.3.1.1. Participant's Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Lonza
      • 11.3.2.1. Participant's Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Inno Biologics Sdn Bhd
      • 11.3.3.1. Participant's Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Rentschler Biotechnologies GmbH
      • 11.3.4.1. Participant's Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. JRS PHARMA
      • 11.3.5.1. Participant's Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. AGC Biologics
      • 11.3.6.1. Participant's Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. ProBioGen
      • 11.3.7.1. Participant's Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
      • 11.3.8.1. Participant's Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Toyobo Co. Ltd.
      • 11.3.9.1. Participant's Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Samsung Biologics
        • 11.3.10.1.1. Participant's Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. Thermo Fisher Scientific, Inc.
      • 11.3.11.1. Participant's Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Binex Co., Ltd.
      • 11.3.12.1. Participant's Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. WuXi Biologics
      • 11.3.13.1. Participant's Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. AbbVie, Inc.
      • 11.3.14.1. Participant's Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. ADMA Biologics, Inc.
      • 11.3.15.1. Participant's Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Catalent, Inc
      • 11.3.16.1. Participant's Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Cambrex Corporation
      • 11.3.17.1. Participant's Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Pfizer Inc.
      • 11.3.18.1. Participant's Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Siegfried Holding AG
      • 11.3.19.1. Participant's Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 4 Global Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 6 Global Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 7 Global Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 8 Global Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 9 Global Biopharmaceutical Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
  • Table 10 North America Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 12 North America Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 13 North America Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 14 North America Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 15 North America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 16 North America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 17 U.S. Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 18 U.S. Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 19 U.S. Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 20 U.S. Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 21 U.S. Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 22 U.S. Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 23 Canada Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 24 Canada Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 25 Canada Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Canada Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 27 Canada Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 28 Canada Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 29 Mexico Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 30 Mexico Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 31 Mexico Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Mexico Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 33 Mexico Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 34 Mexico Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 35 Europe Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 36 Europe Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 37 Europe Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 38 Europe Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Europe Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 40 Europe Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 41 Europe Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 42 Germany Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 43 Germany Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 44 Germany Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 45 Germany Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 46 Germany Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 47 Germany Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 48 UK Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 49 UK Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 50 UK Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 51 UK Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 52 UK Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 53 UK Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 54 France Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 55 France Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 56 France Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 57 France Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 58 France Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 59 France Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 60 Italy Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 61 Italy Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 62 Italy Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 63 Italy Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 64 Italy Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 65 Italy Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 66 Spain Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 67 Spain Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 68 Spain Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 69 Spain Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 70 Spain Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 71 Spain Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 72 Denmark Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 73 Denmark Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 74 Denmark Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 75 Denmark Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 76 Denmark Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 77 Denmark Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 78 Sweden Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 79 Sweden Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 80 Sweden Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 81 Sweden Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 82 Sweden Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 83 Sweden Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 84 Norway Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 85 Norway Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 86 Norway Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 87 Norway Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 88 Norway Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 89 Norway Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 90 Asia Pacific Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 91 Asia Pacific Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 92 Asia Pacific Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 93 Asia Pacific Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 94 Asia Pacific Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 95 Asia Pacific Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 96 Asia Pacific Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 97 China Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 98 China Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 99 China Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 100 China Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 101 China Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 102 China Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 103 Japan Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 104 Japan Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 105 Japan Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 106 Japan Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 107 Japan Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 108 Japan Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 109 India Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 110 India Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 111 India Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 112 India Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 113 India Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 114 India Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 115 South Korea Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 116 South Korea Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 117 South Korea Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 118 South Korea Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 119 South Korea Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 120 South Korea Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 121 Australia Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 122 Australia Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 123 Australia Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 124 Australia Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 125 Australia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 126 Australia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 127 Thailand Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 128 Thailand Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 129 Thailand Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 130 Thailand Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 131 Thailand Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 132 Thailand Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 133 Latin America Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 134 Latin America Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 135 Latin America Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 136 Latin America Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 137 Latin America Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 138 Latin America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 139 Latin America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 140 Brazil Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 141 Brazil Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 142 Brazil Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 143 Brazil Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 144 Brazil Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 145 Brazil Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 146 Argentina Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 147 Argentina Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 148 Argentina Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 149 Argentina Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 150 Argentina Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 151 Argentina Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 152 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 153 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 154 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 155 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 156 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 157 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 158 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 159 South Africa Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 160 South Africa Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 161 South Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 162 South Africa Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 163 South Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 164 South Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 165 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 166 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 167 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 168 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 169 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 170 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 171 UAE Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 172 UAE Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 173 UAE Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 174 UAE Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 175 UAE Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 176 UAE Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 177 Kuwait Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 178 Kuwait Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 179 Kuwait Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 180 Kuwait Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 181 Kuwait Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 182 Kuwait Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biopharmaceutical Contract Manufacturing, Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Dynamics
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 PESTEL Analysis, By SWOT Analysis
  • Fig. 12 Regional Marketplace: Key Takeaways
  • Fig. 13 Global Biopharmaceutical Contract Manufacturing, for Mammalian, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biopharmaceutical Contract Manufacturing, for Non-mammalian, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biopharmaceutical Contract Manufacturing, for Process Development, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biopharmaceutical Contract Manufacturing, for Downstream, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biopharmaceutical Contract Manufacturing, for Upstream, 2018 - 2030 (USD Million)
  • Fig. 18 Global Biopharmaceutical Contract Manufacturing, for Fill & Finish Operations, 2018 - 2030 (USD Million)
  • Fig. 19 Global Biopharmaceutical Contract Manufacturing, for Analytical & QC Studies, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biopharmaceutical Contract Manufacturing, for Packaging & Labelling & Labelling, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biopharmaceutical Contract Manufacturing, for Biologics, 2018 - 2030 (USD Million)
  • Fig. 23 Global Biopharmaceutical Contract Manufacturing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 24 Global Biopharmaceutical Contract Manufacturing, for Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biopharmaceutical Contract Manufacturing, for Vaccines, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biopharmaceutical Contract Manufacturing, for Antisense, RNAi, & Molecular Therapy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 28 Global Biopharmaceutical Contract Manufacturing, for Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 29 Global Biopharmaceutical Contract Manufacturing, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 30 Global Biopharmaceutical Contract Manufacturing, for Finished Drug Product, 2018 - 2030 (USD Million)
  • Fig. 31 Global Biopharmaceutical Contract Manufacturing, for Clinical, 2018 - 2030 (USD Million)
  • Fig. 32 Global Biopharmaceutical Contract Manufacturing, for Commercial, 2018 - 2030 (USD Million)
  • Fig. 33 Global Biopharmaceutical Contract Manufacturing, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 34 Global Biopharmaceutical Contract Manufacturing, for Autoimmune Diseases, 2018 - 2030 (USD Million)
  • Fig. 35 Global Biopharmaceutical Contract Manufacturing, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 36 Global Biopharmaceutical Contract Manufacturing, for Cardiovascular Diseases, 2018 - 2030 (USD Million)
  • Fig. 37 Global Biopharmaceutical Contract Manufacturing, for Metabolic Diseases, 2018 - 2030 (USD Million)
  • Fig. 38 Global Biopharmaceutical Contract Manufacturing, for Neurology, 2018 - 2030 (USD Million)
  • Fig. 39 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Regional Outlook, 2024 & 2030
  • Fig. 41 North America Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Canada Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Europe Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 UK Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 France Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 China Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Japan Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Australia Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Africa Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Saudi Arabia Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 UAE Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Kuwait Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)